FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)
ID: 342752Type: Forecasted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Eligible Applicants

Small Businesses

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/342752
Timeline
    Description

    The Food and Drug Administration (FDA) is forecasting a grant opportunity titled "FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)" aimed at facilitating federal financial assistance for high-quality conferences and scientific meetings that align with the FDA's mission. This grant program is designed to support events such as symposiums, seminars, and workshops that focus on topics impacting public health, thereby enhancing research and investigation in relevant areas. The estimated total program funding is $1,000,000, with approximately 30 awards expected to be granted, and interested applicants can reach out to Janelle Fundersburg at Janelle.Fundersburg@fda.hhs.gov or by phone at 301-796-2533 for further information. The synopsis is expected to be posted on October 13, 2022, with a closing date for applications on April 12, 2023.

    Point(s) of Contact
    Janelle Fundersburg Grants Management Specialist
    (301) 796-2533
    Janelle.Fundersburg@fda.hhs.gov
    Files
    No associated files provided.
    Similar Opportunities
    Collaborations to Enhance Drug Development and Regulatory Science
    Food and Drug Administration
    The Food and Drug Administration (FDA) is inviting applications for a federal grant titled "Collaborations to Enhance Drug Development and Regulatory Science." This opportunity aims to establish cooperative agreements that support Public-Private Partnerships and collaborative activities under the Critical Path Initiative, focusing on innovative projects that enhance drug product development, advanced manufacturing, and the translation of scientific discoveries into therapeutics. The initiative is crucial for fostering innovation in drug safety, efficacy, quality, and performance, with a total funding ceiling of $5 million available for six expected awards in fiscal year 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call (240) 402-7610 for further information.
    Critical Path Public Private Partnerships Clinical Trials Optional
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a grant opportunity titled "Critical Path Public Private Partnerships Clinical Trials Optional," aimed at supporting the continuation of existing consortia groups established by the Critical Path Institute. This initiative seeks applications to manage and maintain these groups, fostering innovative projects in research, education, and outreach to enhance drug product innovation and accelerate the development of therapeutics. The grant, which has an award ceiling and floor of $20 million, is expected to result in one award, with applications being accepted for the fiscal year 2024. Interested applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610 for further information.
    NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIH Research Conference Grant (R13) to support high-quality scientific conferences that align with public health and the scientific missions of participating Institutes and Centers. This initiative encourages diverse participation and requires applicants to submit a detailed diversity plan, conference objectives, and logistical arrangements, while ensuring that costs align with actual project needs. The funding is crucial for fostering inclusive environments at scientific gatherings, with applications evaluated based on significance, innovation, approach, and diversity. Interested applicants can find more information and guidelines at the NIH website, with the application submission period opening on March 12, 2024, and closing on January 8, 2027. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Flexible Funding Model-Infrastructure Development and Maintenance for State Manufactured Food Regulatory Programs (U2F) Clinical Trials Not Allowed
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity titled "Flexible Funding Model-Infrastructure Development and Maintenance for State Manufactured Food Regulatory Programs (U2F)," aimed at enhancing state manufactured food regulatory programs. This cooperative agreement seeks to support the development and maintenance of Manufactured Food Regulatory Program Standards (MFRPS) to ensure high-quality regulatory frameworks that improve food safety and reduce foodborne illness hazards. Eligible applicants include state, tribal, and territorial food safety programs with existing FDA food safety inspection contracts or those willing to enter into such contracts, with funding amounts ranging from $340,000 to $1,285,000 per year. Interested parties can contact Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610 for further information, with applications expected to align with the fiscal year 2024 timeline.
    Manufactured Foods Flexible Funding Model (MF-FFM)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity titled "Manufactured Foods Flexible Funding Model (MF-FFM)" aimed at advancing a nationally integrated food safety system. This cooperative agreement seeks to support initiatives related to Manufactured Food Regulatory Program Standards (MFRPS), dietary supplement safety, and state compliance and enforcement infrastructure, with a focus on enhancing food safety practices across jurisdictions. The program is critical for ensuring that state regulatory programs maintain high-quality standards and best practices in food safety. Interested applicants, which include state, local, territorial, and tribal agencies, as well as non-profit training entities collaborating with higher education institutions, can reach out to Gordana Zuber at gordana.zuber@fda.hhs.gov or by phone at 301-348-1747 for further details. The estimated project start date is July 1, 2023, with approximately 50 awards expected under this discretionary funding opportunity.
    Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a federal grant opportunity titled "Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)." This grant aims to fund clinical trials that evaluate the efficacy and safety of products intended to address unmet needs in rare diseases or conditions, with the goal of increasing the number of approved treatments in this area. The initiative is crucial for enhancing drug development for rare diseases, thereby potentially improving patient outcomes. Interested applicants, including higher education institutions, nonprofits, for-profit organizations, and various levels of government, can reach out to Kimberly Pendleton at Kimberly.Pendleton@fda.hhs.gov or call 240-402-7610 for more information. The opportunity is currently posted for the fiscal year 2025, with no cost-sharing or matching requirements.
    Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a federal grant opportunity titled "Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required." This grant aims to fund clinical trials that evaluate the efficacy and safety of products intended to address unmet needs in rare neurodegenerative diseases affecting both children and adults, thereby increasing the number of approved treatments in this critical area. The initiative is part of the FDA's broader effort to enhance drug development for rare diseases, which is vital for improving health outcomes in affected populations. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for more information, with funding amounts ranging from $650,000 to $900,000 for the fiscal year 2025.
    Cooperative Agreement to Support Effective Dissemination of Clinical Practice Guidelines
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "Cooperative Agreement to Support Effective Dissemination of Clinical Practice Guidelines." This initiative aims to support the dissemination of clinical practice guidelines, particularly those developed with prior FDA cooperative agreements, by requiring applicants to propose a comprehensive plan for developing, evaluating, and distributing materials that facilitate this dissemination, with a strong emphasis on equity. The funding for this opportunity has an award ceiling and floor of $1,000,000, with one award expected to be made in fiscal year 2025. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further details.
    Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)" aimed at supporting innovative studies that advance medical product development for rare diseases with unmet needs. The objective of this grant is to facilitate the collection of high-quality data that addresses critical knowledge gaps and removes barriers to progress in the field of rare diseases, ultimately impacting the development of medical products. This initiative is crucial for enhancing understanding and treatment options for rare diseases, which often lack sufficient research and resources. Interested applicants can apply for funding up to $400,000, with no cost-sharing requirements, and should direct inquiries to Kimberly Pendleton at Kimberly.Pendleton@fda.hhs.gov or call 240-402-7610. The opportunity is currently open and will be available for the fiscal year 2025.
    Retail Food Safety Regulatory Association Collaboration
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a federal grant opportunity titled "Retail Food Safety Regulatory Association Collaboration" aimed at enhancing state, local, tribal, and territorial (SLTT) retail food safety programs. This cooperative agreement seeks to support non-profit national organizations affiliated with higher education institutions, focusing on reducing food-borne illness risk factors through research, intervention strategies, and other activities. The initiative is crucial for advancing a nationally integrated food safety system and alleviating the burden of foodborne illnesses. The estimated total program funding is $4 million, with approximately five awards expected, and interested applicants can contact Danielle Head at danielle.head@fda.hhs.gov or (301) 796-2984 for further information. The opportunity is open for the fiscal year 2026 and was last updated on August 4, 2025.